胸腺五肽联合辛伐他汀对COPD合并肺动脉高压患者血清PAF-AH、esRAGE水平的影响  

Effects of thymopentin combined with simvastatin on serum PAF-AH and esRAGE levels in patients with COPD complicated with pulmonary hypertension

作　　者：李江鸿 芦莎 谢琳霞 赵亚妮 马宣 LI Jianghong;LU Sha;XIE Linxia;ZHAO Yani;MA Xuan(Respiratory and Critical Care Medicine Department,Xi'an International Medical Center Hospital,Xi'an 710100;Respiratory Medicine Department,Huainan Sunshine Xinkang Hospital,Huainan 232000,China)

机构地区：[1]西安国际医学中心医院呼吸与危重症医学科,陕西西安710100 [2]淮南阳光新康医院呼吸内科,安徽淮南232000

出　　处：《临床医学研究与实践》2025年第5期33-36,共4页Clinical Research and Practice

基　　金：宁夏自然科学基金项目(No.NZ13139)。

摘　　要：目的分析胸腺五肽联合辛伐他汀对慢性阻塞性肺疾病(COPD)合并肺动脉高压患者血清血小板活化因子乙酰水解酶(PAF-AH)、内源性分泌型晚期糖基化终末产物受体(esRAGE)水平的影响。方法选取2020年6月至2023年6月于西安国际医学中心医院诊疗的100例COPD合并肺动脉高压患者作为研究对象,以电脑随机数字表法将其分为对照组和观察组,每组50例。对照组予以辛伐他汀治疗,观察组予以胸腺五肽联合辛伐他汀治疗。比较两组的临床疗效、PAF-AH、esRAGE、炎症因子水平及肺功能指标。结果观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗1个月后,两组的PAF-AH及esRAGE水平均升高,且观察组高于对照组(P<0.05)。治疗1个月后,两组的C反应蛋白(CRP)、白细胞介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)水平均降低,且观察组低于对照组(P<0.05)。治疗1个月后,两组的用力肺活量(FVC)、呼气流量峰值(PEF)及第1秒用力呼气容积/用力肺活量(FEV1/FVC)均升高,且观察组高于对照组(P<0.05)。结论胸腺五肽联合辛伐他汀治疗COPD合并肺动脉高压的效果显著,可改善血清PAF-AH及esRAGE水平,减轻炎症反应,促进肺功能恢复。Objective To analyze the effects of thymopentin combined with simvastatin on serum platelet-activating factor-acetyl hydrolase(PAF-AH)and endogenous secretory receptor for advanced glycation end products(esRAGE)levels in patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary hypertension.Methods A total of 100 patients with COPD complicated with pulmonary hypertension who were treated in Xi'an International Medical Center Hospital from June 2020 to June 2023 were selected as the research objects.The patients were divided into control group and observation group by computer random number table method,with 50 cases in each group.The control group was treated with simvastatin,and the observation group was treated with thymopentin combined with simvastatin.The clinical efficacy,PAF-AH,esRAGE,inflammatory factors levels and lung function indexes were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was stastically significant(P<0.05).After 1 month of treatment,the levels of PAF-AH and esRAGE in the two groups increased,and those in the observation group were higher than the control group(P<0.05).After 1 month of treatment,the levels of C-reactive protein(CRP),interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).After 1 month of treatment,the forced vital capacity(FVC),peak expiratory flow(PEF)and forced expiratory volume in one second/forced vital capacity(FEV1/FVC)of the two groups increased,and those of the observation group were higher than the control group(P<0.05).Conclusion Thymopentin combined with simvastatin in the treatment of COPD patients with pulmonary hypertension has significant effect,which can improve the levels of serum PAF-AH and esRAGE,reduce the inflammatory response and promote the recovery of lung function.

关 键 词：胸腺五肽 辛伐他汀 慢性阻塞性肺疾病 肺动脉高压 

分 类 号：R563[医药卫生—呼吸系统]